Last reviewed · How we verify
Loteprednol Etabonate Ophthalmic Gel [Lotemax]
Loteprednol Etabonate Ophthalmic Gel [Lotemax] is a Small molecule drug developed by Virginia Polytechnic Institute and State University. It is currently in Phase 1 development.
At a glance
| Generic name | Loteprednol Etabonate Ophthalmic Gel [Lotemax] |
|---|---|
| Sponsor | Virginia Polytechnic Institute and State University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loteprednol Etabonate Ophthalmic Gel [Lotemax] CI brief — competitive landscape report
- Loteprednol Etabonate Ophthalmic Gel [Lotemax] updates RSS · CI watch RSS
- Virginia Polytechnic Institute and State University portfolio CI
Frequently asked questions about Loteprednol Etabonate Ophthalmic Gel [Lotemax]
What is Loteprednol Etabonate Ophthalmic Gel [Lotemax]?
Loteprednol Etabonate Ophthalmic Gel [Lotemax] is a Small molecule drug developed by Virginia Polytechnic Institute and State University.
Who makes Loteprednol Etabonate Ophthalmic Gel [Lotemax]?
Loteprednol Etabonate Ophthalmic Gel [Lotemax] is developed by Virginia Polytechnic Institute and State University (see full Virginia Polytechnic Institute and State University pipeline at /company/virginia-polytechnic-institute-and-state-university).
What development phase is Loteprednol Etabonate Ophthalmic Gel [Lotemax] in?
Loteprednol Etabonate Ophthalmic Gel [Lotemax] is in Phase 1.